TY - JOUR
T1 - Genetics and genomics of arrhythmic risk
T2 - current and future strategies to prevent sudden cardiac death
AU - Scrocco, Chiara
AU - Bezzina, Connie R.
AU - Ackerman, Michael J.
AU - Behr, Elijah R.
N1 - Funding Information:
C.S. and E.R.B. are supported by the Robert Lancaster Memorial Fund sponsored by McColl’s Retail Group Ltd. C.R.B. is supported by the Dutch Heart Foundation (CVON Predict2 project), the Netherlands Organization for Scientific Research (VICI fellowship, 016.150.610) and Fondation Leducq (17CVD02). M.J.A. is supported by the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program.
Publisher Copyright:
© 2021, Springer Nature Limited.
PY - 2021/11
Y1 - 2021/11
N2 - A genetic risk of sudden cardiac arrest and sudden death due to an arrhythmic cause, known as sudden cardiac death (SCD), has become apparent from epidemiological studies in the general population and in patients with ischaemic heart disease. However, genetic susceptibility to sudden death is greatest in young people and is associated with uncommon, monogenic forms of heart disease. Despite comprehensive pathology and genetic evaluations, SCD remains unexplained in a proportion of young people and is termed sudden arrhythmic death syndrome, which poses challenges to the identification of relatives from affected families who might be at risk of SCD. In this Review, we assess the current understanding of the epidemiology and causes of SCD and evaluate both the monogenic and the polygenic contributions to the risk of SCD in the young and SCD associated with drug therapy. Finally, we analyse the potential clinical role of genomic testing in the prevention of SCD in the general population.
AB - A genetic risk of sudden cardiac arrest and sudden death due to an arrhythmic cause, known as sudden cardiac death (SCD), has become apparent from epidemiological studies in the general population and in patients with ischaemic heart disease. However, genetic susceptibility to sudden death is greatest in young people and is associated with uncommon, monogenic forms of heart disease. Despite comprehensive pathology and genetic evaluations, SCD remains unexplained in a proportion of young people and is termed sudden arrhythmic death syndrome, which poses challenges to the identification of relatives from affected families who might be at risk of SCD. In this Review, we assess the current understanding of the epidemiology and causes of SCD and evaluate both the monogenic and the polygenic contributions to the risk of SCD in the young and SCD associated with drug therapy. Finally, we analyse the potential clinical role of genomic testing in the prevention of SCD in the general population.
UR - http://www.scopus.com/inward/record.url?scp=85106229410&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106229410&partnerID=8YFLogxK
U2 - 10.1038/s41569-021-00555-y
DO - 10.1038/s41569-021-00555-y
M3 - Review article
C2 - 34031597
AN - SCOPUS:85106229410
SN - 1759-5002
VL - 18
SP - 774
EP - 784
JO - Nature Reviews Cardiology
JF - Nature Reviews Cardiology
IS - 11
ER -